Intelligent Bio's Q2 Loss Widens As FDA Application Planned For Year-End; Stock Down
Intelligent Bio Solutions Inc. (INBS) reported a wider Q2 net loss of $12.47M, or $8.44 per share, despite a 38% revenue increase to $4.21M. The company plans to submit a FDA 510(k) clearance application by year-end for its drug screening system. INBS stock is down 16.27% to $2.69.
How this was made
The 30-second read
Why it matters
The FY2026 earnings release shows a widening loss despite revenue growth, and the company’s plan to file a 510(k) could be a catalyst.
Market read
Earnings and regulatory filing plan provide fresh data for traders; stock already down sharply on the news.
What to watch
Cash runway of $3.99M may fund continued R&D without immediate dilution.
Background
Intelligent Bio Solutions Inc. (INBS) is a medical‑technology company developing rapid, non‑invasive drug‑testing devices.
Ticker impact
Intelligent Bio reported FY2026 loss of $12.47M, revenue up 38% and plans FDA 510(k) filing by year‑end; stock down 16.27%.
Further downside pressure in near term unless FDA filing news is positive.
Loss widened YoY and revenue growth insufficient to offset; market already reacted with a 16% drop.
Market effects
Highlights challenges for med‑tech diagnostics firms seeking FDA clearance.
Limited to US micro‑cap biotech segment.
Minimal; primarily affects niche investors in diagnostic technology.
Counterpoint
Potential upside if FDA clearance is granted quickly, unlocking revenue growth.
Key entities
- CompanyIntelligent Bio Solutions Inc.
Medical‑technology firm developing fingerprint drug‑screening system.
